MARKET

TLPH

TLPH

Talphera Inc
NASDAQ
0.8975
-0.0038
-0.42%
After Hours: 0.8600 -0.0375 -4.18% 17:14 05/14 EDT
OPEN
0.9100
PREV CLOSE
0.9013
HIGH
0.9400
LOW
0.8600
VOLUME
274.57K
TURNOVER
--
52 WEEK HIGH
1.570
52 WEEK LOW
0.3800
MARKET CAP
46.58M
P/E (TTM)
-2.6640
1D
5D
1M
3M
1Y
5Y
1D
CorMedix Q1 net income rises to $38.6 million; revenue more than doubled to $127.4 million
PUBT · 15h ago
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 16h ago
Talphera targets Niyad PMA filing in 2026 and potential approval in 2027 as NEPHRO enrollment surpasses 50%
Seeking Alpha · 1d ago
Talphera Q1 2026 Earnings Call Transcript
Benzinga · 1d ago
Talphera reports Q1 EPS (4c) vs. (10c) last year
TipRanks · 1d ago
Talphera Q1 net loss narrows as costs rise on higher development spending
Reuters · 1d ago
Talphera Q1 EPS $(0.04) Beats $(0.07) Estimate, Sales $0.00 Down From $27.000K YoY
Benzinga · 1d ago
Talphera GAAP EPS of -$0.04 beats by $0.04
Seeking Alpha · 1d ago
More
About TLPH
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company’s portfolio consists of nafamostat product candidates and pre-filled syringe product candidates. The Company’s lead product candidate, Niyad, is a lyophilized formulation of nafamostat and is being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit. Niyad is used in adult patients undergoing continuous renal replacement therapy (CRRT). LTX-608 is its nafamostat formulation for direct IV infusion being explored as an investigational product for one or more indications, including antiviral treatment, or treatment of acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), or acute pancreatitis. The Company’s two ready-to-use pre-filled syringe (PFS) product candidates include Fedsyra and phenylephrine.

Webull offers Talphera Inc stock information, including NASDAQ: TLPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TLPH stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TLPH stock methods without spending real money on the virtual paper trading platform.